More data from the STOMP (Study of Tecovirimat for Mpox) trial presented at CROI 2025, in San Francisco, confirmed that tecovirimat does not reduce the time to clinical resolution of clade II mpox lesions or improve pain among adults, according to Timothy Wilkin, MD, MPH, a professor of medicine and the chief of the Division of Infectious Diseases and Global Public Health at the University of California, San Diego.
STOMP was a randomized, double-blind, placebo-controlled